Predictors of infliximab efficacy in patients with severe attack of ulcerative colitis
Aim of investigation. Biological therapy by monoclonal antibodies against tumor necrosis factor (infliximab) allows to avoid colectomy at steroid-resistant severe attack of ulcerative colitis. High cost of such treatment and risk of adverse events related to it requires definition of strict indicati...
Saved in:
Main Authors: | A. O. Golovenko, I. L. Khalif, O. V. Golovenko, V. V. Veselov |
---|---|
Format: | Article |
Language: | Russian |
Published: |
Gastro LLC
2013-10-01
|
Series: | Российский журнал гастроэнтерологии, гепатологии, колопроктологии |
Subjects: | |
Online Access: | https://www.gastro-j.ru/jour/article/view/1233 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Features of development and progression of colorectal cancer on a background of ulcerative colitis
by: I. L. Khalif, et al.
Published: (2012-02-01) -
Efficacy of mesalazine at ulcerative colitis with nutritional failure
by: A. V. Korolyov, et al.
Published: (2015-03-01) -
Effectiveness of tacrolimus therapy in refractory ulcerative colitis compared to infliximab with propensity score matching
by: Takeo Yoshihara, et al.
Published: (2025-01-01) -
Diagnostic value of interleukins 23 and 17 in the assessment of ulcerative colitis severity
by: M.V. Stoikevych, et al.
Published: (2024-12-01) -
Mesalazine use tactics in the ulcerative colitis patients
by: A. V. Korolev, et al.
Published: (2013-03-01)